107 results
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
14 May 24
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
4:47pm
Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein … of a Phase 1 clinical trial that met its primary endpoint of safety and reactogenicity affirming the safety of proteins produced by Dyadic's C1
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
28 Mar 24
Dyadic Reports 2023 Full Year Results and Recent Company Progress
4:07pm
, with a conversion price of $1.79 and no warrants
Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety …
Entered into several fully funded vaccine and antibody projects covering more than twelve targets since announcing topline clinical safety data from First
8-K
EX-99.1
tordxjl
11 Mar 24
Dyadic Announces Closing of Private Placement of
8:45am
8-K
EX-99.1
uxr 58plfud12vmfqz
8 Nov 23
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:09pm
8-K
EX-99.1
36i dpekxs544kpw
6 Oct 23
Other Events
4:20pm
8-K
EX-99.1
rzb2h3 sv53i
9 Aug 23
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:08pm
8-K
EX-99.1
z2x 35qu72twja59q15
10 May 23
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
4:35pm
8-K
EX-10.1
5qljt
12 Apr 23
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
8:30am
8-K
EX-99.1
yjcqi1msi4hg1scr8
29 Mar 23
Dyadic Reports 2022 Year End Results and Recent Company Progress
4:32pm
8-K
EX-99.1
vsvdy
10 Nov 22
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
4:06pm